DefinitionThis section has been translated automatically.
Synthetic, direct thrombin inhibitor (see below hirudin).
IndicationThis section has been translated automatically.
Heparin-induced thrombocytopenia, other thromboembolic diseases.
You might also be interested in
Pregnancy/nursing periodThis section has been translated automatically.
No application recommended!
Dosage and method of useThis section has been translated automatically.
Refludan: Initial 0.4 mg/kg bw i.v. as a bolus, then 0.15 mg/kg bw/hour as a continuous infusion over 2-10 days.
Undesirable effectsThis section has been translated automatically.
Frequent bleeding. Rare allergic skin reactions, localized to the injection site.
ContraindicationThis section has been translated automatically.
Hypersensitivity to lepirudine, hirudines or other ingredients. Do not administer in cases of acute bleeding or increased bleeding tendency, advanced kidney function impairment, age over 65 years, pregnancy, lactation.
PreparationsThis section has been translated automatically.
Refludan
Note(s)This section has been translated automatically.
Safety for children has not been proven.
LiteratureThis section has been translated automatically.
- Lewis BE et al (2007) Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 5: 57-68
Prof. Dr. med. Peter Altmeyer